

inflammatory disease. In response to the instant Office Communication, Applicant has elected psoriasis as a single disclosed species of inflammatory disease for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

For the avoidance of any possible doubt, the first full paragraph on page 1 of the Response to Restriction Requirement mailed on October 31, 2006, is amended to read as follows:

In response to the Restriction Requirement set forth in the Office Action mailed January 19, 2007, Applicant hereby provisionally elects Group I, claims 1-38, for continued examination. Applicant further elects the following species: (A) homo-multimeric compound that binds to at least two PSGL-1 proteins; (D) antigen binding domain of an anti-PSGL-1 antibody or a fragment thereof; psoriasis; and (A) absence of detecting the number of T cells or detecting the biological activity of the T cells before / after administration of multimeric compounds.


Similarly, for the avoidance of any possible doubt, the last paragraph on page 2 of the Response to Restriction Requirement mailed on October 31, 2006, is amended to read as follows:

In response to the Restriction Requirement, Applicant has elected Group I, (A) homo-multimeric compound that binds to at least two PSGL-1 proteins; (D) antigen binding domain of an anti-PSGL-1 antibody or a fragment thereof; psoriasis; and (A) absence of detecting the number of T cells or detecting the biological activity of the T cells before / after administration of multimeric compounds, for examination. This election is made with traverse.

Applicant believes the application is in condition for allowance. An early and favorable response is solicited.

Dated: March 1, 2007

Respectfully submitted,

By 

Alan W. Steele, M.D., Ph.D.

Registration No.: 45,128

WOLF, GREENFIELD & SACKS, P.C.

Federal Reserve Plaza

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

(617) 646-8000